Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | LCAT | P04180 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956150 | 0.76 | PRKAA2 (0.52) | DPP4THRB | |
| SCHEMBL3064433 | 0.75 | PARP1 (0.46) | LCAT | |
| SCHEMBL2139666 | 0.74 | NFKB1 (0.69) | MALT1HCRTR1HCRTR2CHRM4 | |
| SCHEMBL1990732 | 0.74 | MALT1 (0.59) | HRH3MALT1USP30LCATHCRTR1 | |
| SCHEMBL20064100 | 0.73 | HRH3 (0.51) | HRH3MALT1USP30LCATHCRTR1 | |
| SCHEMBL7718659 | 0.72 | MYC (0.47) | — | |
| SCHEMBL12467241 | 0.72 | HTR2B (0.42) | HRH3AOC3 | |
| SCHEMBL3063005 | 0.72 | SPR (0.39) | HRH3 | |
| SCHEMBL28020356 | 0.72 | SPR (0.44) | HRH3 | |
| Hydrochloric Acid SCHEMBL3288531 | 0.72 | HRH3 (0.50) | HRH3MALT1USP30LCATHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20090304632-A1 | HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20080241100-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYTOKINE | 4SC AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | HRH3 130/4885MALT1 1601/4885USP30 2835/4885 |
| US-20080241100-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYTOKINE | IL2, IL17A, IFNG | HRH3 312/4885MALT1 3226/4885USP30 3472/4885 |
| US-20090304632-A1 | HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | HRH3 116/4885MALT1 686/4885USP30 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.